Stem cell therapy in ophthalmology for MS opthalmology theory exam

Reading File

Finding Sources

Searching PubMed

stem cell therapy ophthalmology

Searching the Web

stem cell therapy in ophthalmology exam notes limbal stem cell deficiency retinal

Finding Sources

Reading File

Stem Cell Therapy in Ophthalmology

1. Introduction

Stem cells are undifferentiated cells capable of self-renewal and differentiation into specialized cell types. In ophthalmology, they have moved from "adjunct/experimental" to standard-of-care in ocular surface disease and are in advanced clinical trials for retinal disease. Exam relevance centers on limbal stem cells (cornea) and retinal/RPE stem cells, with mesenchymal stem cells (MSCs) for immunomodulation.

2. Types of Stem Cells Used

Type	Source	Main ophthalmic use
Limbal epithelial stem cells (LESCs)	Palisades of Vogt (limbus)	Corneal surface reconstruction
Embryonic stem cells (ESCs)	Blastocyst	RPE/photoreceptor replacement (AMD)
Induced pluripotent stem cells (iPSCs)	Reprogrammed somatic cells	Autologous RPE sheets, disease modeling
Mesenchymal stem cells (MSCs)	Bone marrow, adipose, umbilical cord	Uveitis, optic neuropathy, immunomodulation
Oral mucosal epithelial cells	Buccal mucosa	Alternative to limbal graft (COMET)
Conjunctival/Muller glia-derived progenitors	Retina	Experimental retinal regeneration

3. Ocular Surface — Limbal Stem Cell Deficiency (LSCD)

This is the best-established clinical application and the most commonly asked topic.

Etiology

Acquired: chemical/thermal burns, Stevens-Johnson syndrome, ocular cicatricial pemphigoid, chronic contact lens wear, multiple surgeries, aniridia-related keratopathy, chronic limbitis
Inherited: aniridia, ectodermal dysplasia

Clinical features: conjunctivalization of cornea, persistent epithelial defects, corneal neovascularization, loss of Palisades of Vogt, irregular epithelium, chronic pain/photophobia. Diagnosis confirmed by impression cytology (goblet cells on cornea) - Kanski's Clinical Ophthalmology, p. 5355 area.

Management ladder

Conservative: preservative-free lubricants, punctal occlusion, autologous serum eye drops (20% q.i.d.), bandage contact lens, short-course topical steroids - The Wills Eye Manual
Surgical debridement for partial LSCD
Stem-cell-based surgery for total/complete LSCD:
- CLAU (Conjunctival Limbal Autograft) - from healthy fellow eye, unilateral disease
- CLAL (Conjunctival Limbal Allograft) - living-related or cadaveric donor, bilateral disease (needs systemic immunosuppression)
- KLAL (Keratolimbal Allograft) - cadaveric, larger limbal tissue
- CLET (Cultivated Limbal Epithelial Transplantation) - small limbal biopsy expanded ex vivo on amniotic membrane/fibrin, then transplanted; the only cell-based therapy formally approved (EU, as "Holoclar")
- SLET (Simple Limbal Epithelial Transplantation) - Sangwan et al. (2012), Indian innovation; small limbal biopsy pieces distributed directly onto amniotic membrane over the cornea in situ, no ex vivo culture needed - cheap, single-stage, widely used in India, high-yield exam topic
- COMET (Cultivated Oral Mucosal Epithelial Transplantation) - autologous, avoids immunosuppression, used in bilateral total LSCD
If stem cell therapy fails or ocular surface is too hostile: keratoprosthesis (Boston KPro type I/II, MOOKP)

Global Consensus (Cornea, 2020) grades LSCD as partial/total and unilateral/bilateral, guiding the choice among the above.

4. Retina — Stem Cell Applications

Age-related macular degeneration (AMD)

RPE is lost early in dry AMD/geographic atrophy; strategy is RPE cell replacement using hESC- or iPSC-derived RPE, delivered as cell suspension or pre-formed monolayer sheets on a scaffold
Aim: rescue photoreceptors by restoring RPE support (phagocytosis of outer segments, visual cycle, growth factor secretion) rather than direct vision restoration
Early-phase trials show safety and graft survival; functional visual gains remain modest

Retinitis pigmentosa / inherited retinal dystrophies

Photoreceptor precursor cell transplantation and retinal progenitor cell injections are being trialed; a 2023 systematic review/meta-analysis (PMID 37798796) found stem cell therapy for inherited retinal disease shows favorable safety with variable/modest visual acuity benefit - evidence still preliminary.

Uveitis

MSCs and MSC-derived extracellular vesicles are being explored for their immunomodulatory (not regenerative) effect - suppressing T-cell activation and pro-inflammatory cytokines. A 2024 systematic review of preclinical studies (PMID 38600361, Eye) supports efficacy signals in animal models but notes lack of human trial data.

Glaucoma

Experimental work on trabecular meshwork stem/progenitor cells to restore outflow function - still preclinical.

Optic neuropathy

MSC and neural stem cell approaches for retinal ganglion cell/optic nerve protection - largely animal-model stage.

5. Advantages vs Limitations

Advantages: restores anatomically appropriate, self-renewing tissue; SLET/CLET avoid large donor tissue harvest; autologous options (SLET, COMET, iPSC-RPE) avoid lifelong immunosuppression.

Limitations/challenges

Immune rejection with allogeneic grafts (CLAL, KLAL, allogeneic hESC-RPE)
Tumorigenic risk with pluripotent stem cells (ESC/iPSC) - teratoma risk
Ethical concerns with embryonic stem cells
Limited long-term functional (visual acuity) data for retinal trials
Success depends on ocular surface milieu - dry eye, symblepharon, and limbal niche health affect graft take
High cost and limited availability of cell-culture facilities for CLET

6. Recent Evidence Check

Recent systematic reviews/meta-analyses (last ~2-3 years) largely support the library textbook framework but add nuance:

Inherited retinal disease stem cell therapy: safety established, efficacy modest (PMID 37798796)
MSC therapy for uveitis: promising in preclinical models only, human data still lacking (PMID 38600361)

These don't contradict standard teaching but confirm that retinal/uveitis stem cell therapy remains investigational, while corneal (limbal) stem cell therapy is the only clinically mature, exam-testable "real world" application (CLET approved in EU; SLET widely practiced).